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Abstract
Rationale Seizures occur when the excitability of brain cir-
cuits is not sufficiently restrained by inhibitory mechanisms.
Although modafinil is reported to reduce GABA-activated
currents and extracellular GABA levels in the brain, the drug
exerts anticonvulsant effects in animal studies.
Objectives The aim of this study was to determine the effects
of modafinil and its metabolites (sulfone and carboxylic acid)
on the anticonvulsant action of four classical antiepileptic
drugs (AEDs)—carbamazepine (CBZ), phenobarbital (PB),
phenytoin (PHT), and valproate (VPA).
Methods Anticonvulsant activity was assessed with the max-
imal electroshock seizure threshold (MEST) test andMES test
in mice. Brain concentrations of AEDs were measured to as-
certain any pharmacokinetic contribution to the observed an-
ticonvulsant effects.
Results Intraperitoneal injection of 75 mg kg−1 of modafinil
or its metabolites significantly elevated the threshold for
electroconvulsions in mice, whereas 50 mg kg−1 of each com-
pound enhanced the anticonvulsant activity of CBZ, PHT, and
VPA, but not that of PB. A 25-mg kg−1 dose of modafinil or its
sulfone metabolite enhanced anticonvulsant activity of VPA.
Modafinil and its metabolites (50 mg kg−1) did not alter total
brain concentrations of PB and VPA but did elevate CBZ and
PHT.
Conclusions Enhancement of anticonvulsant actions of VPA
by modafinil in the mouse MES model is a pharmacodynamic
effect. Collectively, our data suggest that modafinil may be a
safe and beneficial adjunct to the therapeutic effects of AEDs
in human patients.
Keywords Antiepileptic drugs .Maximal
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ANOVA Analysis of variance
Introduction
Modafinil (diphenylmethylsulfinylacetamide) is wake-
promoting medication approved for the treatment of narcolep-
sy, shift work sleep problems, and obstructive sleep apnea
(Ballon and Feifel 2006; Minzenberg and Carter 2008). In
the past decade, there has been a marked increase in off-
label use of modafinil for a variety of indications (Peñaloza
et al. 2013). As a nonamphetamine stimulant with low abuse
liability, modafinil may be a safe alternative for treatment of
fatigue syndrome and psychiatric disorders such as treatment-
resistant depression and attention deficit/hyperactivity disor-
der (Minzenberg and Carter 2008; Swanson et al. 2006). De-
spite the widespread clinical use of modafinil, the precise
mechanisms underlying its therapeutic efficacy are complex
and not well understood (for review, see Ballon and Feifel
2006; Minzenberg and Carter 2008).
Modafinil is reported to affect many central neurotransmit-
ter systems: dopamine, norepinephrine, 5-hydroxytryptamine,
glutamate, GABA, histamine, and orexin. Moreover, it is sug-
gested that excitatory effects of modafinil may be due to wide-
spread disinhibition of excitatory networks caused by in-
creased electrical coupling and decreased input resistance
among electrically coupled neurons (Garcia-Rill et al. 2007).
Initial preclinical studies indicated that stimulant effects of
modafinil are distinct from those of amphetamine and may
not involve dopamine systems (Duteil et al. 1990; Simon
et al. 1995). However, more recent studies show that
modafinil interacts with dopamine transporter (DAT) proteins
to block dopamine uptake and elevate extracellular dopamine
in the central nervous system of rats and in humans (Volkow
et al. 2009; Zolkowska et al. 2009). Nevertheless, modafinil
has a number of nondopaminergic effects which include acti-
vation of α1 adrenergic receptors (Duteil et al. 1990), en-
hancement of 5-hydroxytryptamine function (Ferraro et al.
2000), inhibition of GABA release (Ferraro et al. 1997,
1998), and stimulation of glutamate and histamine release
(Ferraro et al. 1999; Ishizuka et al. 2003)
Even though modafinil is reported to reduce GABA-
activated currents and extracellular GABA levels in different
brain regions, the drug exerts antiepileptic effects (Chen et al.
2007). Specifically, modafinil is able to reduce seizure activity
in the maximal electroshock (MES) model and in the
pentylenetetrazole (PTZ)-kindling model. Surprisingly, the
sulfone and acid metabolites of modafinil are reported to exert
anticonvulsant activity in the MES model (Chatterjie et al.
2004).
It is generally accepted that seizures occur when the
excitability of brain circuits is not sufficiently restrained
by inhibi tory mechanisms (Nadler 2012) . The
neurotransmitter changes associated with epileptic foci
include decreased GABA activity mainly at GABA-A
receptors and altered activity at calcium, sodium, chlo-
ride, and potassium channels. Increased intracellular and
decreased extracellular calcium concentrations, as well
as decreased GABA-ergic presynaptic inhibition, are im-
portant factors in the hyperexcitability that contributes
in epileptogenesis.
The aim of our study was to further explore the
e f f e c t s o f moda f i n i l and i t s two me t abo l i t e s ,
diphenylmethylsufonylacetamide (i.e., sulfone metabolite)
and diphenylmethylthioacetic acid (i.e., acid metabolite),
on the threshold for electroconvulsions and on the protec-
tive activity of four classical antiepileptic drugs (AEDs):
carbamazepine (CBZ), phenobarbital (PB), phenytoin
(PHT), and valproate (VPA) in the mouse MES-induced
seizure model. Additionally, because modafinil is a DAT
blocker, we wished to compare the anticonvulsant
effects of modafinil to the prototypical DAT blocker
1 - [2 - [b i s ( 4 - f l uo ropheny l )me thoxy ]e t hy l ] - 4 - (3 -
phenylpropyl)piperazine (GBR 12909). The threshold for
electroconvulsions and the MES test are established ex-
perimental models of tonic-clonic seizures and, to a cer-
tain extent, of partial convulsions with or without second-
ary generalization in humans (Löscher et al. 1991). Both
tests are used as standard screening procedures for iden-
tifying new anticonvulsant agents or treatments which can
be combined with classical AEDs (Löscher et al. 1991).
Therefore, these in vivo seizure models were selected for
evaluation of the effects of modafinil and other test drugs
alone as well as in combination with classical AEDs. Fi-
nally, total brain AED concentrations were measured with
a fluorescence polarization immunoassay to ascertain
whether effects of modafinil or its metabolites were relat-
ed to altered pharmacokinetics of AEDs.
Materials and methods
Animals and experimental conditions
Adult male Swiss mice (weighing 22–26 g) were kept in col-
ony cages with free access to food and tap water, housed under
standardized housing conditions (natural light-dark cycle,
temperature of 23±1 °C, relative humidity of 55±5 %). After
7 days of adaptation to laboratory conditions, animals were
randomly assigned to experimental groups each composed of
eight mice. Each mouse was used only once, and all tests were
performed between 08:00 a.m. and 03:00 p.m. Experiments
were performed after a minimum 30-min period of acclima-
tion to the experimental room. Procedures involving animals
and their care were conducted in accordance with current Eu-
ropean Community and Polish legislation on animal
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experimentation. Additionally, all efforts were made to mini-
mize animal suffering and to use only the number of animals
necessary to produce reliable scientific data. The experimental
protocols and procedures described in this manuscript were
approved by the Second Local Ethics Committee at the Uni-
versity of Life Sciences in Lublin (license nos. 3/2011,
5/2012, 16/2012) and complied with the European Commu-
nities Council Directive of 24 November 1986 (86/609/EEC).
Drugs
Th e f o l l ow i n g d r u g s we r e u s e d : mod a f i n i l ,
diphenylmethylsufonylacetamide (sulfone metabolite),
diphenylmethylthioacetic acid (acid metabolite), and
1 - [2 - [b i s ( 4 - f l uo ropheny l )me thoxy ]e t hy l ] - 4 - (3 -
phenylpropyl)piperazine HCl (GBR 12909) were synthe-
sized by Dr. T. E. Prisinzano (Department of Medicinal
Chemistry, The University of Kansas, Lawrence KS,
USA), carbamazepine (CBZ—a gift from Polpharma,
Starogard Gdański, Poland), phenobarbital (PB—Polfa,
Kraków, Poland), phenytoin (PHT—Polfa, Warszawa, Po-
land), and valproate (VPA—magnesium salt—kindly do-
nated by ICN-Polfa S.A., Rzeszów, Poland). All drugs,
except for VPA and GBR 12909, were suspended in an
aqueous 1 % solution of Tween 80 (Sigma, St. Louis,
MO, USA); VPA and GBR 12909 were directly dissolved
in distilled water. All drugs were administered intraperi-
toneally (i.p.), in a volume of 10-ml kg−1 body weight, at
the following pretreatment times: PHT 120 min, PB
60 min, modafinil, its metabolites, GBR 12909, CBZ
and VPA 30 min before electroconvulsions, and brain
sampling for the measurement of AED concentrations.
The pretreatment times before testing of the AEDs were
based upon information about their biological activity
from the literature (Löscher et al. 1991) and our previous
experiments (Luszczki et al. 2009a, b, 2010a, b). The
pretreatment time (30 min) before testing modafinil, sul-
fone, and acid metabolites, or GBR 12909 were based on
our previous experiments and literature data (Chatterjie
et al. 2004; Zolkowska et al. 2009).
Electroconvulsions
Electroconvulsions were induced by applying an alternating
current (50 Hz; 500 V) via ear clip electrodes from a rodent
shocker generator (type 221; Hugo Sachs Elektronik, Frei-
burg, Germany). The stimulus duration was 0.2 s. Tonic hind
limb extension was used as the endpoint. This apparatus was
used to induce seizures in two methodologically different ex-
perimental approaches: maximal electroshock seizure thresh-
old (MEST) test and MES test (Löscher et al. 1991).
Maximal electroshock seizure threshold (MEST) test
The MEST test was first used to assess the anticonvulsant
effects of modafinil, sulfone, and acid metabolites or GBR
12909 administered alone. In this test, at least four groups of
control mice, each consisting of eight animals, were chal-
lenged with currents of varying intensities ranging between
5 and 8 mA so that 10–30, 30–50, 50–70, and 70–90 % of
animals exhibited the endpoint. After establishing the current
intensity-effect curve (i.e., current intensity in mAvs percent-
age of mice convulsing) for each dose of modafinil, its me-
tabolites, or GBR 12909, the electroconvulsive threshold was
calculated according to the log-probit method of Litchfield
and Wilcoxon (1949). The electroconvulsive threshold was
expressed as the median current strength value (CS50 in mA)
predicted to produce tonic hind limb extension in 50 % of the
animals tested. This experimental procedure was performed
for various increasing doses of modafinil and sulfone and acid
metabolites (12.5–75 mg kg−1) or GBR 12909 (6.25–
50 mg kg−1), until the thresholds for electroconvulsions of
tested compounds were statistically different from that of the
control animals. Only doses of modafinil, sulfone, and acid
metabolite or GBR 12909 that did not significantly affect the
seizure threshold in the MEST test were selected for testing in
combination with four classical AEDs in the MES test (see
below). This approach allowed us to rule out any contribution
of the intrinsic anticonvulsant efficacy of tested substances in
the effects observed in combination with the AEDs in the
MES test. Subsequently, the percentage increase in CS50
values for animals injected with increasing doses of modafinil,
sulfone, and acid metabolites and GBR 12909 over the control
(vehicle-treated animals) was calculated. The doses of
modafinil, its metabolites and GBR 12909, and their resultant
percentage of threshold increase over the control (vehicle-
treated animals) were graphically plotted in rectangular coor-
dinates of the Cartesian plot system and examined with least-
squares linear regression analysis. From the linear regression
equation, the TID20 values were determined, as recommended
by Löscher et al. (1991) and Swinyard et al. (1952). This
experimental procedure has been described in more detail in
our earlier studies (Luszczki and Czuczwar 2005, 2007;
Luszczki et al. 2013).
Maximal electroshock seizure (MES) test
In the MES test, mice were challenged with a current of the
fixed intensity (25 mA) that was 4–5-fold higher than the CS50
value in vehicle-treated control mice (Löscher et al. 1991).
These parameters of stimulation (maximal electroshock) typ-
ically result in all mice responding with tonic hind limb ex-
tension immediately after stimulation. The AEDs adminis-
tered alone and their combination with modafinil, its metabo-
lites, or GBR 12909 were tested for their ability to increase the
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number of animals not responding with tonus (i.e., protected
from tonic hind limb extension) after stimulation. Again, at
least four groups of mice, each consisting of eight animals and
treated with a different dose of the AEDs alone or in combi-
nation with modafinil, sulfone and acid metabolites or GBR
12909, were challenged with a current of 25 mA to yield 10–
30, 30–50, 50–70, and 70–90 % of animals protected from
tonic seizures. After constructing a dose-effect curve (i.e.,
dose in mg kg−1 vs percentage of mice protected), the protec-
tivemedian effective dose (ED50) value of the AED testedwas
calculated according to a log-probit method by Litchfield and
Wilcoxon (1949). Each ED50 value represented a dose of the
AED (in mg kg−1) predicted to protect 50 % of mice tested
against MES-induced extension of the hind limbs. Modafinil,
its two metabolites, and GBR 12909 were tested for their
ability to affect the anticonvulsive potency of AEDs. As men-
tioned earlier, modafinil, sulfone, and acid metabolites or
GBR 12909 were administered in doses that per se had no
effect on seizure threshold in the MEST test. In this experi-
mental protocol, an increase in the anticonvulsant potency of
the AED tested in combination with modafinil, sulfone, and
acid metabolites or GBR 12909 would be reflected by a lower
ED50 value of the test AED (i.e., lower dose of test drug was
necessary to protect 50 % of mice challenged). In the present
study, CBZ was administered at doses ranging between 2 and
18 mg kg−1, PB at doses ranging between 10 and 35 mg kg−1,
PHT at doses ranging between 4 and 14 mg kg−1, and VPA at
doses ranging between 175 and 400 mg kg−1. These AED
doses suppressed tonic seizures in 10–90 % of mice subjected
to the MES test.
Measurement of total brain antiepileptic drug concentrations
Pharmacokinetic evaluation of total brain AED concentrations
was performed for the combinations of modafinil, sulfone,
and acid metabolites or GBR 12909 with CBZ, PB, PHT,
and VPA (at the doses that corresponded to their ED50 values
from the MES test). Specifically, mice pretreated with a given
AED alone or in combination with modafinil, sulfone, and
acid metabolites or GBR 12909 were decapitated at times
reflecting the peak of maximum anticonvulsant effects for
the drugs in the MES test. The whole brains of mice were
removed from the skulls, weighed, harvested, and homoge-
nized using Abbott buffer (1:2 weight/volume; Abbott Labo-
ratories, North Chicago, IL, USA) in an Ultra-Turrax T8 ho-
mogenizer. The homogenates were then centrifuged at 10,000
g for 10 min, and the supernatant samples of 100 μl were
collected and then analyzed for AED content. Total brain con-
centrations of CBZ, PB, PHT, and VPA were measured by a
fluorescence polarization immunoassay using an analyzer
(Abbott TDx) and manufacturer-supplied reagent kits (Abbott
Laboratories, North Chicago, IL, USA). Total brain AED con-
centrations are expressed in μg g−1 of wet brain tissue as
means ± standard error of the mean (S.E.M.) of at least eight
separate brain preparations.
Step-through passive avoidance task
The effects of combinations of modafinil (50 mg kg−1), its
metabolites (50 mg kg−1), or GBR 12909 (25 mg kg−1) with
different classical AEDs were quantified by the step-through
passive avoidance task of Venault et al. (1986). AEDs were
administered at doses corresponding to their ED50 values from
Table 1 Influence of modafinil (MOD), sulfone (SULF), and acid
(ACID) derivatives of MOD and GBR12909 on the threshold for
electroconvulsions in mice
Treatment (mg kg−1) CS50 (mA) n TI (%)
Vehicle 6.12±0.40 16 –
MOD (12.5) 5.95±0.44 24 −2.78
MOD (25) 6.29±0.48 16 2.78
MOD (50) 7.52±0.54 24 22.88
MOD (75) 8.29±0.48* 24 35.46
F (4; 99)=4.702; P=0.0016
Vehicle 5.69±0.51 24 –
SULF (12.5) 6.50±0.52 24 14.24
SULF (25) 6.92±0.40 32 21.62
SULF (50) 7.53±0.48 24 32.34
SULF (75) 9.04±0.47*** 16 58.88
F (4; 115)=5.494; P=0.0004
Vehicle 5.69±0.51 24 –
ACID (12.5) 6.42±0.50 32 12.83
ACID (25) 6.96±0.48 32 22.32
ACID (50) 7.67±0.72 32 34.80
ACID (75) 8.98±0.45** 24 57.82
F (4; 189)=4.414; P=0.0022
Vehicle 6.31±0.43 16 –
GBR (6.25) 7.02±0.48 16 11.25
GBR (12.5) 7.52±0.55 24 19.18
GBR (25) 7.93±0.62 32 25.67
GBR (50) 9.12±0.45* 24 44.53
F (4; 107)=3.135; P=0.0176
Results are presented as median current strengths (CS50 in mA ± S.E.M.)
required to produce tonic hind limb extension in 50 % of animals tested.
MOD, SULF, ACID, and GBR were administered i.p. at 30 min before
electroconvulsions. Statistical analysis of data was performed with one-
way ANOVA followed by the post hoc Tukey-Kramer test for multiple
comparisons. Additionally, the threshold for control animals was consid-
ered as a baseline (reference) value, allowing for the subsequent calcula-
tion of a percentage of threshold increase (TI) in animals after MOD,
SULF, ACID, and GBR administration. n number of animals tested at
those current strength intensities, whose seizure effects ranged between
16 and 84 % according to Litchfield and Wilcoxon (1949)
FF-statistics from one-way ANOVA, P probability from one-way ANOVA
*P<0.05, **P<0.01, and ***P<0.001 vs the respective control group
(vehicle-treated animals)
2466 Psychopharmacology (2015) 232:2463–2479
the MES test. Each animal received an AED either alone
or in combination either with modafinil, sulfone, and acid
metabolites or with GBR 12909 on the first day before
training. The time before commencement of the training
session (after drug administration) in the step-through
passive avoidance task was identical to that for the MES
test. Subsequently, the animals were placed in an illumi-
nated box (10×13×15 cm) connected to a larger dark box
(25×20×15 cm) equipped with an electric grid floor. En-
trance of the animals to the dark box was punished by an
adequate electric footshock (0.6 mA for 2 s). The animals
that did not enter the dark compartment were excluded
from subsequent experimentation. On the following day
(24 h later), the pretrained animals were placed again into
the illuminated box and observed for up to 180 s. Mice
that avoided the dark compartment for 180 s were consid-
ered as having remembered the task. The time the mice
took to enter the dark box was noted, and the median
latencies (retention times) with 25th and 75th percentiles
were calculated.
Grip strength test
The effects of combinations of modafinil (50 mg kg−1),
sulfone and acid metabolites (50 mg kg−1), or GBR 12909
(25 mg kg−1) with different classical AEDs at doses cor-
responding to their ED50 values from the MES test on
skeletal muscular strength in mice were quantified by
the grip strength test of Meyer et al. (1979). The grip
strength apparatus (BioSeb, Chaville, France) comprised
a wire grid (8×8 cm) connected to an isometric force
transducer (dynamometer). The mice were lifted by the
tails so that their forepaws could grasp the grid. The mice
were then gently pulled backward by the tail until the grid
was released. The maximal force exerted by the mouse
before losing grip was recorded. The mean of three mea-
surements for each animal was calculated, and subse-
quently, the mean maximal force of eight animals per
group was determined. The muscular strength in mice is
expressed in N (newtons) as the means ± S.E.M. of at
least eight determinations.
Fig. 1 a–d Effect of modafinil
(MOD) (a), its sulfone (SULF)
(b) and acid (ACID) (c)
metabolites, and GBR12909
(GBR) (d) on the threshold test
for electroconvulsions (MEST) in
mice. Left panel graphs illustrate
current intensity–response
relationships for tonic hind limb
extension in the threshold test for
electroconvulsions in mice for
MOD, SULF, ACID, and GBR.
All tested drugs were
administered i.p. at 30 min before
electroconvulsions. Data points
indicate percentage of animals
protected. Each point represents
eight mice. Right panel columns
represent median current
strengths (CS50 in mA ± S.E.M.)
for modafinil (a), SULF
metabolite (b), ACID metabolite
(c), and GBR12909 (d), required
to produce tonic hind limb
extension in 50 % of animals
tested. Statistical analysis of data
was performed with one-way
ANOVA followed by the post hoc
Tukey-Kramer test for multiple
comparisons. *P<0.05,
**P<0.01, and ***P<0.001 vs
the respective control group
(vehicle-treated animals)
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Chimney test
The chimney test of Boissier et al. (1960) was used to
quantify the adverse effect potential of classical AEDs
administered in combination with modafinil, its metabo-
lites, or GBR 12909. In this test, the animals had to
climb backwards up a plastic tube (3-cm inner diameter,
30 cm long), and impairment of motor performance was
indicated by the inability of the mice to climb backward
up the transparent tube within 60 s. The acute adverse
effect potentials for the combinations of classical AEDs
with either modafinil, sulfone, and acid metabolites or
GBR 12909 were determined for the AEDs administered
at doses corresponding to their ED50 values from the
MES t e s t w h e n c om b i n e d w i t h m o d a f i n i l
(50 mg kg−1), its metabolites (50 mg kg−1), or GBR
12909 (25 mg kg−1).
Statistics
Both CS50 and ED50 values with their 95 % confidence limits
were calculated by computer log-probit analysis according to
Litchfield and Wilcoxon (1949). Subsequently, the respective
95 % confidence limits were transformed to S.E.M. as de-
scribed previously (Luszczki et al. 2009a). Statistical analysis
of data from the MEST test was performed with one-way
analysis of variance (ANOVA) followed by the post hoc
Tukey-Kramer test for multiple comparisons among four
CS50 values. Statistical analysis of data from the MES test
was performed with one-way ANOVA followed by the post
hoc Tukey-Kramer test for multiple comparisons among three
ED50 values. Total brain AED concentrations were statistical-
ly compared using the unpaired Student’s t test. The results
obtained in the step-through passive avoidance task were sta-
tistically evaluated using Kruskal-Wallis nonparametric
Fig. 2 Dose-threshold increase relationship for modafinil (MOD), its
sulfone (SULF) and acid (ACID) metabolites, and GBR12909 (GBR)
in maximal electroshock seizure threshold (MEST) test in mice. Points
placed on the graph represent threshold increasing doses of MOD, SULF,
ACID, and GBR, experimentally denoted in the MEST test in mice.
Linear regression analysis allowed determination of the equation for
dose-threshold increase relationship for MOD, SULF, ACID, and GBR,
as follows: y=0.637 x−11.29 (R2=0.989) for MOD, y=0.689 x+3.763
(R2=0.956) for SULF, y=0.696 x+3.665 (R2=0.983) for ACID, and y=
0.730 x+8.049 (R2=0.990) for GBR, where y is the threshold increase in
%, x is the drug dose, and R2 is the coefficient of determination. From
these equations, the TID20 (threshold increasing doses by 20 %) for the
MEST test were calculated. In this study, these values were
49.12 mg kg−1 for MOD, 23.57 mg kg−1 for SULF, 23.47 mg kg−1 for
ACID, and 16.37 mg kg−1 for GBR, respectively. The dashed line
indicates threshold increase by 20 % and the respective doses of the
tested compounds in the MEST test, which exerted this (20 %) effect.
MOD, SULF, ACID, and GBR were administered systemically (i.p.),
30 min before the threshold evaluation
Table 2 Effects of modafinil (MOD) on the anticonvulsant action of
carbamazepine (CBZ), phenobarbital (PB), phenytoin (PHT), and
valproate (VPA) in the mouse maximal electroshock (MES)-induced
seizure model
Treatment (mg kg−1) ED50 (mg kg
−1) n
CBZ + vehicle 11.23±1.20 16
CBZ + MOD (25) 7.48±0.75 16
CBZ + MOD (50) 4.28±0.93*** 32
F (2; 61)=11.95; P<0.0001
PB + vehicle 20.80±3.12 24
PB + MOD (25) 19.40±2.20 24
PB + MOD (50) 13.04±1.76 16
F (2; 61)=2.157; P=0.1244
PHT + vehicle 11.00±0.93 16
PHT + MOD (25) 8.44±0.84 16
PHT + MOD (50) 5.35±0.86*** 32
F (2; 61)=9.831; P=0.0002
VPA + vehicle 328.6±13.17 40
VPA + MOD (12.5) 303.5±13.19 40
VPA + MOD (25) 279.1±16.12* 40
VPA + MOD (50) 245.3±10.45** 24
F (3; 140)=5.432, P=0.0015
Results are presented as median effective doses (ED50 in mg kg
−1 ±
S.E.M.) of AEDs, protecting 50 % of animals tested against MES-in-
duced hind limb extension. The AEDs were administered i.p. CBZ
30 min, PHT 120 min, PB 60 min, and VPA 30 min prior to the MES
test. MODwas administered i.p. at 30 min before theMES test. Statistical
analysis of data was performed with one-way ANOVA followed by the
post hoc Tukey-Kramer test for multiple comparisons. n total number of
animals at those doses, whose anticonvulsant effects ranged between 4th
and 6th probit (16 and 84%) according to Litchfield andWilcoxon (1949)
FF-statistics from one-way ANOVA, P probability value from one-way
ANOVA
*P<0.05, **P<0.01, and ***P<0.001 vs the respective control group
(AED + vehicle-treated animals)
2468 Psychopharmacology (2015) 232:2463–2479
ANOVA. The results from the grip strength test were verified
with one-way ANOVA. The data from the chimney test were
statistically analyzed with the Fisher’s exact probability test.
Differences among values were considered statistically signif-
icant if P<0.05. All statistical tests were performed using
GraphPad Prism version 5.0 for Windows (GraphPad Soft-
ware, San Diego, CA, USA).
Results
Influence of modafinil, sulfone, and acid metabolites or GBR
12909 on the threshold for electroconvulsions
Modafinil and its two metabolites administered at a dose of
75 mg kg−1 i.p. significantly increased the threshold for
electroconvulsions in mice (Table 1). The thresholds were
elevated from 6.12±0.40 to 8.29±0.48 mA (F[4,99]=4.70;
P=0.002), from 5.69±0.51 to 9.04±0.47 mA (F[4,115]=5.49;
P=0.0004), and from 5.69±0.51 to 8.98±0.45 mA (F[4,189]=
4.414; P=0.0022) by modafinil and its sulfone and acid metab-
olites, respectively (Table 1, Fig. 1a–d). The experimentally de-
rived CS50 values for animals receiving test compounds at doses
12.5–50mg kg−1 did not significantly differ from that for control
animals subjected to the MEST test (Table 1, Fig. 1a–d). Addi-
tionally, because modafinil is a DAT blocker, we compared the
anticonvulsant effects of modafinil and its twometabolites to the
prototypical DAT blocker—GBR 12909. GBR 12909 adminis-
tered at 50 mg kg−1 i.p. significantly elevated the threshold for
electroconvulsions in mice from 6.31±0.43 to 9.12±0.45 mA
(F[4,107]=3.14; P=0.02) while the doses of 6.25–25 mg kg−1
were ineffective (Table 1, Fig. 1a–d).
The equation for dose-threshold increase relationship for
modafinil, its sulfone, and acid metabolites and GBR were as
Fig. 3 a–d Effects of modafinil
(MOD) on the anticonvulsant
action of carbamazepine (CBZ),
phenobarbital (PB), phenytoin





activity of classical antiepileptic
drugs (AEDs) [CBZ (a), PB (b),
PHT (c), and VPA (d)] alone and
in combination with modafinil
(MOD) in the mouse maximal
electroshock (MES)-induced
seizure model. The AEDs were
administered i.p. CBZ 30min, PB
60 min, PHT 120 min, and VPA
30 min prior to the MES test.
MOD was administered i.p. at
30 min before the MES test. Data
points indicate percentage of
animals protected. Each point
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columns represent median
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−1
± S.E.M.) of AEDs [CBZ (a), PB
(b), PHT (c), and VPA (d)],
protecting 50 % of animals tested
against MES-induced hind limb
extension. Statistical analysis of
data was performed with one-way
ANOVA followed by the post hoc
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comparisons. *P<0.05,
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follows: y=0.637 x−11.29 (R2=0.989) formodafinil, y=0.689 x+
3.763 (R2=0.956) for sulfone metabolite, y=0.696 x+3.665 (R2=
0.983) for acid metabolite, and y=0.730 x+8.049 (R2=0.990) for
GBR12909, where y is the threshold increase in %, x is the drug
dose, andR2 is the coefficient of determination. The experimentally
derived TID20 (dose that increases threshold by 20%) values were
49.12 mg kg−1 for modafinil, 23.57 mg kg−1 for sulfone metabo-
lite, 23.47 mg kg−1 for acid metabolite, and 16.37 mg kg−1 for
GBR12909, respectively, in the MEST test in mice (Fig. 2).
Effects of modafinil, its metabolites, or GBR 12909
on the protective action of carbamazepine, phenobarbital,
phenytoin, and valproate in the mouse maximal electroshock
seizure model
All investigated classical AEDs (CBZ, PB, PHT, and
VPA) adminis te red a lone exhib i ted a c lear-cut
anticonvulsant activity in the MES test in mice (Table 2,
Fig . 3a–d) . When modaf ini l (50 mg kg−1) was
coadministered with CBZ, PHT, and VPA, it significantly
enhanced the anticonvulsant action of AEDs in the MES
test by reducing the ED50 value of CBZ from 11.23±1.20
to 4.28±0.93 mg kg−1 (F[2,61]=11.95; P<0.0001), PHT
from 11.00±0.93 to 5.35±0.86 mg kg−1 (F[2,61]=9.83;
P=0.0002), and VPA from 328.6±13.17 to 245.3±
10.45 mg kg−1 (F[3,140]=5.432; P=0.002) (Table 2,
Fig. 3a–d). Similarly, the sulfone and acid metabolites at
a dose of 50 mg kg−1 significantly enhanced the anticon-
vulsant action of CBZ and VPA (Tables 3 and 4, Figs. 4a–
d and 5a–d). The sulfone reduced the ED50 value of CBZ
from 11.23±1.20 to 5.74±0.82 mg kg−1 (F[2,53]=9.09;
P = 0.0004) and PHT from 11.00 ± 0.93 to 5.95 ±
0.80 mg kg−1 (F[2,61]=8.76; P=0.0005), respectively
(Table 3, Fig. 4a–d). The acid metabolite reduced the
Table 3 Effects of sulfone metabolite of modafinil (SULF) on the
anticonvulsant action of carbamazepine (CBZ), phenytoin (PHT),
phenobarbital (PB), and valproate (VPA) in the mouse maximal
electroshock (MES)-induced seizure model
Treatment (mg kg−1) ED50 (mg kg
−1) n
CBZ + vehicle 11.23±1.20 16
CBZ + SULF (25) 8.30±0.73 16
CBZ + SULF (50) 5.74±0.82*** 24
F (2; 53)=9.086; P=0.0004
PB + vehicle 20.80±3.12 24
PB + SULF (25) 18.17±1.80 16
PB + SULF (50) 13.97±2.09 8
F (2; 45)=1.017; P=0.3700
PHT + vehicle 11.00±0.93 16
PHT + SULF (25) 8.27±0.72 16
PHT + SULF (50) 5.95±0.80*** 32
F (2; 61)=8.763; P=0.0005
VPA + vehicle 328.6±13.17 40
VPA + SULF (12.5) 274.2±10.86 8
VPA + SULF (25) 262.7±10.73** 32
VPA + SULF (50) 226.4±19.75*** 16
F (3; 92)=9.347, P<0.0001
Results are presented as median effective doses (ED50 in mg kg
−1 ±
S.E.M.) of AEDs, protecting 50 % of animals tested against MES-in-
duced hind limb extension. The AEDs were administered i.p. CBZ
30 min, PB 60 min, PHT 120 min, and VPA 30 min prior to the MES
test. SULF derivative of modafinil was administered i.p. at 30 min before
the MES test. Statistical analysis of data was performed with one-way
ANOVA followed by the post hoc Tukey-Kramer test for multiple com-
parisons. n total number of animals used at those doses whose anticon-
vulsant effects ranged between 4th and 6th probit (16 and 84 %) accord-
ing to Litchfield and Wilcoxon (1949)
FF-statistics from one-way ANOVA, P probability value from one-way
ANOVA
**P<0.01 and ***P<0.001 vs the respective control group (AED +
vehicle-treated animals)
Table 4 Effects of acid metabolite of modafinil (ACID) on the
anticonvulsant action of carbamazepine (CBZ), phenytoin (PHT),
phenobarbital (PB), and valproate (VPA) in the mouse maximal
electroshock (MES)-induced seizure model
Treatment (mg kg−1) ED50 (mg kg
−1) n
CBZ + vehicle 11.23±1.20 16
CBZ + ACID (25) 10.22±0.80 16
CBZ + ACID (50) 6.40±0.87** 16
F (2; 45)=6.863; P=0.0025
PB + vehicle 20.80±3.12 24
PB + ACID (25) 20.28±4.05 32
PB + ACID (50) 14.42±2.16 24
F (2; 77)=0.9940; P=0.3748
PHT + vehicle 11.00±0.93 16
PHT + ACID (25) 9.86±0.86 24
PHT + ACID (50) 6.25±0.71** 16
F (2; 53)=7.244; P=0.0017
VPA + vehicle 328.6±13.17 40
VPA + ACID (25) 292.3±19.48 32
VPA + ACID (50) 241.6±14.52*** 32
F (2; 101)=7.944, P=0.0006
Results are presented as median effective doses (ED50 in mg kg
−1 ±
S.E.M.) of AEDs, protecting 50 % of animals tested against MES-in-
duced hind limb extension. The AEDs were administered i.p. CBZ
30 min, PB 60 min, PHT 120 min, and VPA 30 min prior to the MES
test. ACID derivative of modafinil was administered i.p. at 30 min before
the MES test. Statistical analysis of data was performed with one-way
ANOVA followed by the post hoc Tukey-Kramer test for multiple com-
parisons. n total number of animals used at those doses whose anticon-
vulsant effects ranged between 4th and 6th probit (16 and 84 %) accord-
ing to Litchfield and Wilcoxon (1949)
FF-statistics from one-way ANOVA, P probability value from one-way
ANOVA
**P<0.01 and ***P<0.001 vs the respective control group (AED +
vehicle-treated animals)
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ED50 values of CBZ from 11.23 ± 1.20 to 6.40 ±
0.87 mg kg−1 (F[2,45]=6.86; P=0.003) and PHT from
11.00±0.93 to 6.25±0.71 mg kg−1 (F[2,53]=7.24; P=
0.002), respectively (Table 4, Fig. 5a–d). Neither
modafinil nor its metabolites at the dose of 25 mg kg−1
had an impact on the anticonvulsant action of CBZ or
PHT against MES-induced seizures in mice (Tables 2, 3
and 4, Figs. 3a–d, 4a–d, and 5a–d). However, modafinil
and its sulfone metabolite at doses of 25 and 50 mg kg−1,
but not at the dose of 12.5 mg kg−1, significantly
enhanced the anticonvulsant action of VPA (Tables 2
and 3, Figs. 3a–d and 4a–d). Modafinil reduced the
ED50 values of VPA from 328.6±13.17 to 245.3±
10.45 mg kg−1 and 279.1±16.12 mg kg−1 (F[3,140]=
5.43; P<0.002) when administered at doses of 50 and
25 mg kg−1, respectively (Table 2, Fig. 3a–d). Sulfone
metabolite reduced the ED50 values of VPA from 328.6
± 13 .17 to 226 . 4 ± 19 .75 mg kg − 1 and 262 .7 ±
10.73 mg kg−1 (F[3,92]=9.35; P<0.0001; Table 3,
Fig. 4a–d) when administered at doses of 50 and
Fig. 4 a–d Effects of sulfone (SULF) derivative of modafinil on the
anticonvulsant action of carbamazepine (CBZ), phenytoin (PHT),
phenobarbital (PB), and valproate (VPA) in the mouse maximal
electroshock (MES)-induced seizure model. Left panel dose–response
relationships for protective activity of classical antiepileptic drugs
(AEDs) [CBZ (a), PB (b), PHT (c), and VPA (d)] alone and in
combination with SULF derivative of modafinil in the mouse maximal
electroshock (MES)-induced seizure model. The AEDs were
administered i.p. CBZ 30 min, PB 60 min, PHT 120 min, and VPA
30 min prior to the MES test. SULF derivative of modafinil was
administered i.p. at 30 min before the MES test. Data points indicate
percentage of animals protected. Each point represents eight mice.
Right panel columns represent median effective doses (ED50 in
mg kg−1 ± S.E.M.) of AEDs [CBZ (a), PB (b), PHT (c), and VPA (d)],
protecting 50 % of animals tested against MES-induced hind limb
extension. The AEDs were administered i.p. CBZ 30 min, PB 60 min,
PHT 120 min, and VPA 30 min prior to the MES test. SULF derivative of
modafinil was administered i.p. at 30 min before the MES test. Statistical
analysis of data was performed with one-way ANOVA followed by the
post hoc Tukey-Kramer test for multiple comparisons. **P<0.01 and
***P<0.001 vs the respective control group (an AED + vehicle-treated
animals)
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25 mg kg−1, respectively. Acid metabolite when
coadmin i s te red wi th VPA only a t the dose of
50 mg kg−1 significantly enhanced the anticonvulsant ac-
tivity of VPA by reducing its ED50 values from 328.6±
13.17 to 241.6±14.52 mg kg−1 (F[2,101]=7.94; P=
0.0006; Table 4, Fig. 5a–d). Neither modafinil nor its
metabolites significantly alter the anticonvulsant action
of PB in the MES test in mice (Tables 2–4, Figs. 3a–d,
4a–d and 5a–d) . By compar i son , GBR 12909
(25 mg kg−1) when coadministered with CBZ, PB, PHT,
and VPA significantly enhanced the anticonvulsant action
of the latter drugs in the MES test by reducing the ED50
values of CBZ from 15.53±1.04 to 11.15±1.21 mg kg−1
(F[2,77]=4.004; P=0.02), PB from 26.90±2.15 to 15.36
±2.71 mg kg−1 (F[2,61]=4.571; P=0.01), PHT from
12.10±1.20 to 6.98±0.98 mg kg−1 (F[2,69]=5.892; P=
0.004), VPA from 286.7±20.11 to 211.4±11.38 mg kg−1
(F[2,61]=4.535; P=0.02) (Table 5, Fig. 6a–d). GBR
12909 at the dose of 12.5 mg kg−1 did not significantly
influence the effects of any tested AEDs (Table 5,
Fig. 6a–d).
Effect of modafinil, its metabolites, or GBR 12909 on total
brain antiepileptic drug concentrations
As determined by the fluorescence polarization immunoassay
method, modafinil (50 mg kg−1) did not significantly affect
the total brain concentrations of PB or VPA coadministered at
the doses of 13 and 245.3 mg kg−1, respectively (Table 6). In
contrast, modafinil (50 mg kg−1) significantly elevated (by
68 %) the total brain concentration of CBZ coadministered
at the dose of 4.3 mg kg−1 (P<0.05; Table 6). Additionally,
modafinil (50 mg kg−1) significantly increased (by 47 %) the
level of total brain concentration of PHTcoadministered at the
Fig. 5 a–d Effects of acid
(ACID) derivative of modafinil
on the anticonvulsant action of
carbamazepine (CBZ), phenytoin
(PHT), phenobarbital (PB), and
valproate (VPA) in the mouse
maximal electroshock (MES)-
induced seizure model. Left panel
dose–response relationships for
protective activity of classical
antiepileptic drugs (AEDs) [CBZ
(a), PB (b), PHT (c), and VPA
(d)] alone and in combination
with ACID derivative of
modafinil in the mouse maximal
electroshock (MES)-induced
seizure model. The AEDs were
administered i.p. CBZ 30min, PB
60 min, PHT 120 min, and VPA
30 min prior to the MES test.
ACID derivative ofmodafinil was
administered i.p. at 30 min before
the MES test. Data points indicate
percentage of animals protected.
Each point represents eight mice.
Right panel columns represent
median effective doses (ED50 in
mg kg−1 ± S.E.M.) of AEDs,
protecting 50 % of animals tested
against MES-induced hind limb
extension. Statistical analysis of
data was performed with one-way
ANOVA followed by the post hoc
Tukey-Kramer test for multiple
comparisons. **P<0.01 and
***P<0.001 vs the respective
control group (an AED + vehicle-
treated animals)
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dose of 5.4 mg kg−1 (P<0.05; Table 6). Similarly, both me-
tabolites sulfone and acid significantly elevated the levels of
total brain concentrations of CBZ (by 41 % and by 30 %;
P<0.05) and PHT (by 30 and 36 %; P<0.05) and had no
effect of the brain levels of PB and VPA (Table 6). In com-
parison, GBR 12909 coadministered with CBZ, PB, PHT, and
VPA did not significantly affect the total brain levels of the
latter drugs (Table 6).
Effects of modafinil, its metabolites, or GBR 12909, alone
and in combination with various antiepileptic drugs, on motor
coordination, passive avoidance performance, and muscular
strength
Modafinil administered alone at a dose of 50 mg kg−1 did not
affect motor coordination in mice subjected to the chimney
test (Table 7). Similarly, modafinil at 50mg kg−1 did not affect
muscular strength in the grip strength test or alter performance
in mice challenged with the step-through passive avoidance
task (Table 7). When modafinil (50 mg kg−1) was adminis-
tered in combination with CBZ, PB, PHT, or VPA at doses
corresponding to their ED50 values from the MES test, motor
performance in the chimney test, skeletal muscular strength in
the grip strength test, and performance in the passive avoid-
ance task were not significantly affected (Table 7). Similarly,
sulfone and acid metabolites, as well as GBR 12909 alone or
in combination with AEDs, had no significant impact on mo-
tor coordination, passive avoidance performance, or muscular
strength (Table 7).
Discussion
Antiepileptic effects of modafinil and its metabolites have
been previously reported in animal studies which examined
MES and chemoconvulsant PTZ seizure models (Chatterjie
et al. 2004; Chen et al. 2007). The major purpose of this study
was to further characterize the anticonvulsant effects of
modafinil and its two metabolites when administered alone
and in combination with four classical AEDs. We found that
modafinil and its metabolites elevated thresholds for
electroconvulsions in mice, and the same compounds de-
creased the ED50 values of classical AEDs in the mouse
MES model. Because modafinil is known to be a DAT inhib-
itor that increases extracellular dopamine (Minzenberg and
Carter 2008; Zolkowska et al. 2009), we examined the effects
of GBR 12909, a prototypical DAT inhibitor. GBR 12909 had
effects that were similar to modafinil and its metabolites. Im-
portantly, none of the test compounds affected pharmacoki-
netics of PB and VPA when given in combination. Intraperi-
toneal injection of 75 mg kg−1 of modafinil or its metabolites
significantly elevated the threshold for electroconvulsions in
mice, whereas 50 mg kg−1 of each compound enhanced the
anticonvulsant activity of CBZ, PHT, and VPA, but not that of
PB. A 25-mg kg−1 dose of modafinil or the sulfone metabolite
significantly enhanced the anticonvulsant activity of VPA.
Intraperitoneal injection of the DAT blocker GBR 12909 at
25 mg kg−1 had similar effects on the activity of all tested
AEDs. None of the tested compounds, alone or in combina-
tion with AEDs, produced adverse effects.
In the present study, we used linear regression analysis to
unequivocally assess the anticonvulsant potential of
modafinil, its sulfone, and acid metabolites and GBR in the
MEST test in mice. In this seizure model, determining TID20
values (i.e., dose that increases threshold by 20 %) allowed a
direct comparison of the anticonvulsant potency of the tested
compounds. Assessment of the dose-response relationship
with linear regression is a standard and common procedure
in pharmacological studies, especially in those assessing the
anticonvulsant potential of drugs or agents (Löscher et al.
Table 5 Effects of GBR12909 (GBR) on the anticonvulsant action of
carbamazepine (CBZ), phenobarbital (PB), phenytoin (PHT), and
valproate (VPA) in the mouse maximal electroshock (MES)-induced
seizure model
Treatment (mg kg−1) ED50 (mg kg
−1) n
CBZ + vehicle 15.53±1.04 24
CBZ + GBR (12.5) 13.79±1.02 24
CBZ + GBR (25) 11.15±1.21* 32
F (2; 77)=4.004; P=0.0222
PB + vehicle 26.90±2.15 16
PB + GBR (12.5) 19.97±2.17 16
PB + GBR (25) 15.36±2.71* 32
F (2; 61)=4.571; P=0.0141
PHT + vehicle 12.10±1.20 32
PHT + GBR (12.5) 10.22±0.80 16
PHT + GBR (25) 6.98±0.98** 24
F (2; 69)=5.892; P=0.0043
VPA + vehicle 286.7±20.11 16
VPA + GBR (12.5) 261.4±13.96 32
VPA + GBR (25) 211.4±11.38* 16
F (2; 61)=4.535, P=0.0146
Results are presented as median effective doses (ED50 in mg kg
−1 ±
S.E.M.) of AEDs, protecting 50 % of animals tested against MES-in-
duced hind limb extension. The AEDs were administered i.p. CBZ
30 min, PHT 120 min, PB 60 min, and VPA 30 min prior to the MES
test. GBR was administered i.p. at 30 min before the MES test. Statistical
analysis of data was performed with one-way ANOVA followed by the
post hoc Tukey-Kramer test for multiple comparisons. n total number of
animals at those doses, whose anticonvulsant effects ranged between 4th
and 6th probit (16 and 84%) according to Litchfield andWilcoxon (1949)
FF-statistics from one-way ANOVA, P probability value from one-way
ANOVA
*P<0.05 and **P<0.01 vs the respective control group (an AED + ve-
hicle-treated animals)
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1991; Loscher and Wauquier 1996; Swinyard et al. 1952).
With linear regression analysis, it was found that both sulfone
and acid metabolites of modafinil produced anticonvulsant
effects in doses lower than those of the parent drug modafinil.
Since the TID20 values for sulfone (23.57 mg kg
−1) and acid
(23.47 mg kg−1) metabolites of modafinil were lower than the
TID20 value for modafinil (49.12 mg kg
−1), one can ascertain
that both metabolites are more favorable with respect to their
anticonvulsant potency in the MEST test than modafinil. Of
note, the calculation of TID20 values allows for a direct com-
parison of the anticonvulsant effects exerted by the drugs in
the MEST test (Löscher et al. 1991; Luszczki and Czuczwar
2005, 2007; Luszczki et al. 2013; Swinyard et al. 1952).
Considering the results from our study (based on the
TID20 values as determined in the MEST test), it is sur-
prising that a previous study reported modafinil adminis-
tered alone in a dose of 300 mg kg−1 (i.p.) exerts 100 %
protection against MES-induced seizures, while sulfone
and acid metabolites of modafinil used in the same dose
protects 50 and 0 % of animals in the screening mouse
MES test, respectively (Chatterjie et al. 2004). Perhaps,
doses of both metabolites used in the mouse MES model
(300 mg kg−1) were too high and thus produced acute
adverse effects that disturbed evaluation of their anticon-
vulsant effects in the MES test. On the other hand, in our
study, it was found that the TID20 values for sulfone and
acid metabolites of modafinil are almost identical suggest-
ing that in low doses, these compounds should produce
the same anticonvulsant effects. On the contrary, as re-
ported by Chatterjie et al. (2004), sulfone metabolite in
the dose of 300 mg kg−1 exerted a 50 % protection in
mice subjected to the MES test, whereas the acid metab-
olite in the dose of 300 mg kg−1 produced no anticonvul-
sant effects in this seizure model. This fact suggests that
there may be differences between these metabolites when
used in high doses. Nevertheless, more advanced studies
Fig. 6 a–d Effects of GBR12909
(GBR) on the anticonvulsant
action of carbamazepine (CBZ),
phenobarbital (PB), phenytoin
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PHT (c), and VPA (d)] alone and
in combination with GBR12909
(GBR) in the mouse maximal
electroshock (MES)-induced
seizure model. The AEDs were
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are required to investigate this difference between the ef-
fects exerted by sulfone and acid metabolites of
modafinil.
It is important to note that in our study, modafinil admin-
istered systemically (i.p.) increased, in a dose-dependent man-
ner (12.5–75mg kg−1), the threshold for electroconvulsions in
the MEST test in mice. Chen et al. (2007) reported that
modafinil administered i.p. produced anticonvulsant activity
against electroconvulsions in mice. More specifically, the au-
thors documented that modafinil administered i.p. in doses of
22.5, 45, 90, and 180 mg kg−1 protected 50, 70, 90, and 70 %
of the mice subjected to electroconvulsions, respectively. The
apparent discrepancy in potency between the results from our
study and those reported earlier by Chen et al. (2007) may be
explained either by different seizure models or mouse strains
used in experiments. Of note, we applied a current (sine-wave,
0.2-s stimulus duration, 500 V, 25 mA, and 50 Hz) that was
almost identical to that used by Swinyard et al. (1952), where-
as Chen et al. (2007) have used a nonstandard current (0.4-s
stimulus duration and 70 mA) that may produce a different
type of electroconvulsions. Additionally, in our study, we used
male Albino Swiss (BALB/c) mice, whereas Chen et al.
(2007) used male Kunming mice, a strain that is not geneti-
cally homogenous, and experimental data indicate that results
obtained using this mouse strain may significantly differ from
other strains (Shang et al. 2009). Thus, a possible explanation
for the more potent anticonvulsant activity of modafinil ob-
served by Chen et al. (2007) is that the Kunming strain of mice
is more sensitive to modafinil than the BALB/c strain of mice
used in our study. Although this hypothesis is speculative, it
can readily explain the observed difference between the re-
sults presented in our study for modafinil in the MEST test
and those observed by Chen et al. (2007) against
electroconvulsions.
The present pharmacokinetic results revealed that
modafinil and its metabolites (50 mg kg−1) did not alter total
brain concentrations of PB and VPA but did elevate
concentrations of CBZ and PHT. Results presented by
Robertson and Hellriegel (2003) suggest that clinically signif-
icant drug-drug interactions with modafinil are most likely
connected to effects on two hepatic enzymes: CYP3A4/5,
which is the most prevalent human CYP enzyme, and
CYP2C9. Studies using human liver microsomes revealed
that modafinil can cause weak inhibition of CYP3A4/5 (Rob-
ertson and Hellriegel 2003). Such interaction may provide an
explanation for increased brain levels of CBZ in combinations
with modafinil or its metabolites, since CBZ is primarily me-
tabolized by CYP3A4. Additionally, modafinil and its sulfone
metabolite inhibit CYP2C9 in human hepatocytes (Robertson
and Hellriegel 2003), and 2C isoforms are major catalysts of
PHT metabolism in humans (Cuttle et al. 2000).
The MEST test is used to determine the anticonvulsant po-
tential of a variety of compounds, while the mouse MES model
allows evaluation of the effects of tested substances on the
activity of classical and second-generation AEDs with proven
effectiveness in humans (Löscher et al. 1991). Our results indi-
cate that modafinil and its metabolites elevated, in a dose-
dependent manner, the threshold for electroconvulsions in
mice. It is important to note that the dose of modafinil providing
protection in the MEST model shown here (i.e., 75 mg kg−1) is
Table 6 Effect of modafinil (MOD), its sulfone (SULF) and acid
(ACID) metabolites, and GBR12909 (GBR) on total brain
concentrations of classical antiepileptic drugs (AEDs) in mice
Treatment (mg kg−1) Brain concentration
(μg g−1 of wet brain tissue)
CBZ (4.3) + vehicle 2.41±0.48
CBZ (4.3) + MOD (50) 4.05±0.41*
CBZ (5.7) + vehicle 3.76±0.35
CBZ (5.7) + SULF (50) 5.31±0.45*
CBZ (6.4) + vehicle 4.46±0.31
CBZ (6.4) + ACID (50) 5.83±0.38*
CBZ (11.2) + vehicle 6.66±0.42
CBZ (11.2) + GBR (25) 6.92±0.48
PB (13.0) + vehicle 23.56±1.10
PB (13.0) + MOD (50) 24.46±0.98
PB (14.0) + vehicle 23.71±0.86
PB (14.0) + SULF (50) 24.85±1.12
PB (14.4) + vehicle 25.46±0.84
PB (14.4) + ACID (50) 26.16±1.28
PB (15.4) + vehicle 24.18±0.70
PB (15.4) + GBR (25) 26.23±0.86
PHT (5.4) + vehicle 1.39±0.20
PHT (5.4) + MOD (50) 2.04±0.22 *
PHT (6.0) + vehicle 1.65±0.19
PHT (6.0) + SULF (50) 2.34±0.23 *
PHT (6.3) + vehicle 1.70±0.15
PHT (6.3) + ACID (50) 2.32±0.20 *
PHT (7.0) + vehicle 3.22±0.30
PHT (7.0) + GBR (25) 3.54±0.24
VPA (211.4) + vehicle 173.66±10.36
VPA (211.4) + GBR (25) 192.47±13.26
VPA (226.4) + vehicle 276.30±11.55
VPA (226.4) + SULF (50) 302.16±18.18
VPA (241.6) + vehicle 346.98±16.10
VPA (241.6) + ACID (50) 369.86±18.14
VPA (245.3) + vehicle 299.73±15.09
VPA (245.3) + MOD (50) 316.90±18.70
Data are presented as mean concentrations (in μg g−1 ± S.E.M.) for n=8
mice/group. Total brain concentrations of classical AEDs were quantified
using a fluorescence polarization immunoassay technique. Data were
statistically verified by using the unpaired Student’s t test. All drugs were
administered i.p. at doses corresponding to the ED50 value from theMES-
induced seizures. For more detail, see the legend of Tables 2–5.
*P<0.05 vs the respective control group (AED-treated animals)
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below the dose necessary to stimulate robust motor activity. By
contrast, the doses of GBR 12909 providing protection are in
the range of motor stimulant doses. For example, Paterson et al.
(2010) showed that 150 mg kg−1 of modafinil and 15 mg kg−1
of GBR 12909 elicit equivalent locomotor activation in mice.
Thus, it seems that anticonvulsant effects of modafinil de-
scribed herein may not be related solely to changes in central
dopaminergic activity.
Modafinil and its metabolites at the subprotective dose of
50 mg kg−1 (the dose that by itself did not significantly increase
the threshold for electroconvulsions) potentiated the anticonvul-
sant activity of CBZ, PHT, and VPA against MES-induced sei-
zures in mice. By contrast, modafinil and its metabolites at the
subprotective dose had no significant impact on the protective
action of PB in the mouse MES model. The comparator drug
GBR 12909 at the dose of 50 mg kg−1 significantly elevated the
threshold for electroconvulsions in the MEST test, and in a
subprotective dose of 25 mg kg−1 potentiated the anticonvulsant
activity of CBZ, PB, PHT, and VPA against MES-induced sei-
zures inmice. Chatterjie et al. (2004) reported that modafinil and
its metabolites at 30 mg kg−1 provide protection against MES-
induced seizures with effectiveness ranging from 50 to 25 %
after intraperitoneal application in rats. In mice, modafinil ad-
ministered intraperitoneally at a dose of 300 mg kg−1 protected
100 % of animals against MES-induced seizures, while sulfone
metabolite provided only a 50 % protection and intermediate
acid was toxic at that dose (Chatterjie et al. 2004).
Previous literature implicates the involvement of norepi-
nephrine rather than dopamine in seizure activity. Pretreat-
ment with alpha-1 receptor antagonist terazosin reverses the
anticonvulsant effect of modafinil in the MES model, while
dopamine receptor (D1 and D2) antagonists have no effect
(Chen et al. 2007), which confirms the involvement of norad-
renergic system. Catecholamine systems, in particular norepi-
nephrine, are implicated in modulating seizure susceptibility
in many animal models. In rodent seizure models, alpha-1
Table 7 Effects of modafinil (MOD), its sulfone (SULF), and acid (ACID) metabolites, GBR12909 (GBR) and their combinations with classical
antiepileptic drugs (AEDs) on passive avoidance performance, muscular strength, and motor performance in mice
Treatment (mg kg−1) Retention time (s) Grip strength (N) Motor coordination impairment
Vehicle 180 (180; 180) 0.917±0.054 0/8
MOD (50) + vehicle 180 (123.5; 180) 0.908±0.053 0/8
CBZ (4.3) + MOD (50) 180 (123.5; 180) 0.915±0.057 0/8
PB (13.0) + MOD (50) 180 (140; 180) 0.896±0.050 0/8
PHT (5.4) + MOD (50) 180 (125; 180) 0.926±0.055 0/8
VPA (245.3) + MOD (50) 164.5 (110.5; 180) 0.903±0.051 1/8
Vehicle 180 (180; 180) 0.987±0.046 0/8
SULF (50) + vehicle 180 (180; 180) 0.957±0.058 0/8
CBZ (5.7) + SULF (50) 180 (180; 180) 0.943±0.053 1/8
PB (14.0) + SULF (50) 180 (180; 180) 0.951±0.046 0/8
PHT (6.0) + SULF (50) 180 (180; 180) 0.930±0.049 0/8
VPA (226.4) + SULF (50) 180 (125.8; 180) 0.895±0.050 1/8
Vehicle 180 (180; 180) 0.987±0.046 0/8
ACID (50) + vehicle 180 (133.5; 180) 0.961±0.050 0/8
CBZ (6.4) + ACID (50) 180 (180; 180) 0.929±0.049 1/8
PB (14.4) + ACID (50) 180 (170; 180) 0.922±0.051 0/8
PHT (6.3) + ACID (50) 180 (180; 180) 0.955±0.062 0/8
VPA (241.6) + ACID (50) 175.5 (112.5; 180) 0.902±0.060 1/8
Vehicle 180 (180; 180) 0.987±0.046 0/8
GBR (25) + vehicle 180 (133.5; 180) 0.937±0.042 1/8
CBZ (11.2) + GBR (25) 180 (180; 180) 0.979±0.040 2/8
PB (15.4) + GBR (25) 180 (170.5; 180) 0.953±0.059 1/8
PHT (7.0) + GBR (25) 180 (180; 180) 0.944±0.057 1/8
VPA (211.4) + GBR (25) 173.5 (112.5; 180) 0.935±0.053 1/8
Results are presented as follows: (1) median retention times (in seconds; with 25th and 75th percentiles in parentheses) from the passive avoidance task,
assessing passive avoidance performance in mice; (2) mean grip strengths (in newtons ± S.E.M.) from the grip strength test, assessing muscular strength
in mice; and (3) number of animals showing motor coordination impairment in the chimney test in mice for n=8 mice/group. Statistical analysis of data
from the passive avoidance taskwas performedwith nonparametric Kruskal-Wallis ANOVA test, whereas those from the grip strength test were analyzed
with one-wayANOVA. The Fisher’s exact probability test was used to analyze the results from the chimney test. All drugs were administered i.p. at times
scheduled from the MES test and at doses corresponding to their ED50 values against MES-induced seizures in mice
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receptor agonists typically exert anticonvulsant effect, while
alpha-2 antagonists have proconvulsant activity (Weinshenker
and Szot 2002). Many clinically used antiepileptic therapies
significantly affect noradrenergic transmission. Classical
AEDs like CBZ, PHT, and VPA increase norepinephrine brain
levels (Baf et al. 1994a, 1994b; Meshkibaf et al. 1995; Sands
et al. 2000). Moreover, genetically altered animals that lack
functional noradrenergic systems have lower seizure thresh-
olds and the anticonvulsant effects of PB, PHT, and ketogenic
diet are abolished (Krahl et al. 1998; Szot et al. 2001; Waller
and Buterbaugh 1985).
The anticonvulsant effects of modafinil plus VPA combi-
nations are pharmacodynamic in nature because modafinil did
not significantly alter total brain VPA concentrations in exper-
imental animals. Although modafinil and its metabolites ele-
vated the total brain CBZ and PHT concentrations by a phar-
macokinetic mechanism in experimental animals, such com-
binations did not produce any negative side effects. Of note,
total brain AED concentrations were verified in this study
with fluorescence polarization immunoassay technique be-
cause, as reported earlier, only total brain AED concentrations
provide the exact classification and characterization of inter-
actions between AEDs in preclinical studies (Cadart et al.
2002; Luszczki et al. 2003a).
It is worth mentioning that acute administration of
AEDs, either alone or in combination with other drugs,
can induce adverse effects in experimental animals. For
instance, it has been reported that some AEDs, adminis-
tered systemically (i.p.), produce dose-dependent reduc-
tions in skeletal muscular strength in mice (Zadrozniak
et al. 2009). With regard to the evaluation of acute adverse
effects in the chimney test, it has been documented that the
combination of tiagabine with VPA (at doses corresponding
to the ED50 values from the MES test) causes acute impair-
ment of motor coordination in mice (Luszczki et al. 2003a).
Additionally, it has been reported that some AEDs (includ-
ing, vigabatrin, tiagabine, gabapentin, and pregabalin) ad-
ministered alone, at doses effective in the MEST test, sig-
nificantly impair performance in mice subjected to the stan-
dard variant of the step-through passive avoidance task
(Luszczki et al. 2003b, 2005). Of note, the step-through pas-
sive avoidance task provides information about the ability of
the tested animals to acquire and retrieve memory (Venault
et al. 1986). However, passive avoidance performance can
be confounded by a wide range of noncognitive factors, in-
cluding pain threshold, motivation, emotionality, and motor
function (Luszczki et al. 2003b, 2005; Podhorna and Brown
2002). Therefore, in the context of the present study, the pas-
sive avoidance test was used as a rapid screening tool for
possible side effects, rather than as a pure memory test.
Based on the aforementioned information, it can be as-
sumed that all the behavioral tests performed in this study
(i.e., chimney test, passive avoidance task, and grip strength
test) are sensitive enough to detect any possible acute adverse
effects in animals receiving the combinations of modafinil, its
metabolites, and GBR12909 with classical AEDs. The lack of
any significant changes in normal behavior in mice exposed to
the tested compounds (i.e., modafinil, its metabolites, and
GBR12909), alone or in combination with AEDs, shows that
these drug treatments produce no measurable adverse effects.
Importantly, acute side effects depend on doses of the tested
compounds; so, higher doses could induce adverse effects in
mice.
In conclusion, our study suggests that the coadministration
of modafinil with classical AEDs might be a promising treat-
ment when applied in clinical settings, especially in patients
with tonic-clonic seizures or partial convulsions with or with-
out secondary generalization. Sedation and cognitive dysfunc-
tion caused by antiepileptic treatments render patients with
epilepsy prone to fatigue and excessive daytime sleepiness.
Concerns over possible increased risk for seizures have pre-
cluded the use of modafinil and other stimulants in patients
with epilepsy (Artsy et al. 2012). However, a recent retrospec-
tive study demonstrated that epileptic patients taking
modafinil for over 10 years had no exacerbation of seizures
(Artsy et al. 2012). Our study is first to report the positive
effect of modafinil and its metabolites on seizure threshold
in rodents. Moreover, our data provide pivotal information
on the beneficial effect of modafinil in combination with clas-
sical AEDs with no exacerbation of side effects. Our data
suggest that further neurochemical and electrophysiological
studies are warranted to confirm that modafinil might be a safe
and efficacious supplementary therapeutic agent in epilepsy
treatment.
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